Encoded Therapeutics is a clinical-stage biotechnology company based in South San Francisco developing one-time precision genetic medicines for severe neurological disorders. Its vector-engineering platform enables cell-type-selective control of gene expression in the brain and peripheral nervous system; lead program ETX101, an AAV9 therapy designed to raise SCN1A expression, is in pivotal development for SCN1A+ Dravet syndrome, with ETX301 for post-amputation neuroma pain next in the pipeline. The company spans discovery through in-house GMP manufacturing.
1
Round
1
Industry
5
Tags
Sep 9, 2026
Latest raise
Funding activity · 1 round
Sep 9, 2026
$275M
Series C+
Led by GV
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
